Session X: Presentation of Selected Colorectal Cancer Abstracts

Chair(s)

• 

  Eric Van Cutsem, MD, PhD

  University Hospital Gasthuisberg/Leuven
  Leuven, Belgium
• 

  Cathy Eng, MD, FACP, FASCO

  Vanderbilt-Ingram Cancer Center
  MD Anderson Cancer Center
  Nashville, United States

Presentations:

• 08:00 – 08:08

  SO-16: FIRE-4 (AIO-KRK-0114): Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab-secondary endpoint
  

  Abstract Presenter: Volker Heinemann
• 08:08 – 08:16

  SO-17: A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
  

  Abstract Presenter: Feng Wang
• 08:16 – 08:26

  Discussant: SO-16, SO-17
  

  Discussant: Sharlene Gill, MD, MPH, MBA – BC Cancer - University of British Columbia
• 08:34 – 08:42

  SO-18: Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies
  

  Abstract Presenter: Lucjan Wyrwicz
• 08:42 – 08:50

  SO-19: Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer
  

  Abstract Presenter: Hiroya Taniguchi
• 08:50 – 08:58

  SO-20: Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
  

  Abstract Presenter: Christophe Borg
• 08:58 – 09:09

  SO-21: Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of clinical trials
  

  Abstract Presenter: Alessandra Raimondi
• 08:58 – 09:09

  Discussant: SO-18, SO-19, SO-20, SO-21
  

  Discussant: Tanios Bekaii-Saab, MD – Mayo Clinic
• 09:09 – 09:17

  SO-22: Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer
  

  Abstract Presenter: Benoist Chibaudel
• 09:17 – 09:25

  LBA SO-23: Real-world evaluation of clinical utility of ColonAiQ® , a blood-based assay for colorectal cancer (CRC) early Detection
  

  Abstract Presenter: Yanbing Ding